SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2002-01-0035. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0035v1 100/4/1185    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sloand, E. Articles by Young, N. S. Search for Related Content PubMed PubMed Citation Articles by Sloand, E. Articles by Young, N. S. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2002, Vol. 100, No. 4, pp. 1185-1191 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Intracellular interferon- in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia Elaine Sloand, Sonnie Kim, Jaroslaw P. Maciejewski, John Tisdale, Dean Follmann, and Neal S. Young From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Immunosuppressive therapy leads to meaningful hematologic improvement in most patients with aplastic anemia (AA). Failure to respond and a later relapse could be due to deficient numbers of hematopoietic stem cells, inadequate treatment of the immune process, or a nonimmunologic etiology. Interferon- (IFN-) has been implicated in the pathophysiology of hematopoietic failure in AA. On the basis of previous findings showing overexpression of IFN- in bone marrow (BM) and peripheral blood (PB) in this disease, we hypothesized that quantitation of IFN- might be applied to predict and monitor responses to immunosuppressive therapy. We measured expression of IFN- in lymphocytes obtained from 123 AA patients, using intracellular 2-color fluorescent staining and flow cytometry. Of 70 patients with severe AA, 36 (51%) demonstrated increased IFN- in circulating T cells. IFN- was detected in only 4 of 53 patients who had recovered from AA. IFN- was not found in PB lymphocytes of patients with other hematologic diseases and heavy transfusion burdens or in healthy volunteers. Among 62 AA patients who were assessed before first treatment with immunosuppressive drugs, 27 of 28 (96%) with circulating IFN--containing T cells subsequently responded to therapy; in contrast, only 11 of 34 (32%) patients whose PB lacked IFN- lymphocytes improved to transfusion independence. IFN--containing lymphocytes declined following treatment in all cases. Of 17 patients assessed during relapse, IFN- was present in T cells prior to the blood count decline in 13, and 12 responded to reinstitution of immunosuppressive drugs. Of 30 BMs tested prior to first treatment, 20, all in responding patients, were positive for IFN-, whereas the negative tests were obtained in 10 nonresponding patients. IFN- is increased in the PB lymphocytes of many patients with AA, and these cells decline with therapy. The presence of intracellular IFN- may predict response to immunosuppressive treatment and also the onset of relapse. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. O. Omokaro, M. J. Desierto, M. A. Eckhaus, F. M. Ellison, J. Chen, and N. S. Young Lymphocytes with Aberrant Expression of Fas or Fas Ligand Attenuate Immune Bone Marrow Failure in a Mouse Model J. Immunol., March 15, 2009; 182(6): 3414 - 3422. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] J. Chen, F. M. Ellison, M. A. Eckhaus, A. L. Smith, K. Keyvanfar, R. T. Calado, and N. S. Young Minor Antigen H60-Mediated Aplastic Anemia Is Ameliorated by Immunosuppression and the Infusion of Regulatory T Cells J. Immunol., April 1, 2007; 178(7): 4159 - 4168. [Abstract] [Full Text] [PDF] E. M. Sloand, L. Pfannes, G. Chen, S. Shah, E. E. Solomou, J. Barrett, and N. S. Young CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins Blood, March 15, 2007; 109(6): 2399 - 2405. [Abstract] [Full Text] [PDF] G. C. Bagby and G. Meyers Bone Marrow Failure as a Risk Factor for Clonal Evolution: Prospects for Leukemia Prevention Hematology, January 1, 2007; 2007(1): 40 - 46. [Abstract] [Full Text] [PDF] N. S. Young, R. T. Calado, and P. Scheinberg Current concepts in the pathophysiology and treatment of aplastic anemia Blood, October 15, 2006; 108(8): 2509 - 2519. [Abstract] [Full Text] [PDF] E. E. Solomou, K. Keyvanfar, and N. S. Young T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia Blood, May 15, 2006; 107(10): 3983 - 3991. [Abstract] [Full Text] [PDF] C. Sugimori, T. Chuhjo, X. Feng, H. Yamazaki, A. Takami, M. Teramura, H. Mizoguchi, M. Omine, and S. Nakao Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia Blood, February 15, 2006; 107(4): 1308 - 1314. [Abstract] [Full Text] [PDF] N. S. Young Pathophysiologic Mechanisms in Acquired Aplastic Anemia Hematology, January 1, 2006; 2006(1): 72 - 77. [Abstract] [Full Text] [PDF] L. C. Platanias Interferon-inducible genes and aplastic anemia Blood, January 1, 2006; 107(1): 2 - 3. [Full Text] [PDF] W. Zeng, A. Miyazato, G. Chen, S. Kajigaya, N. S. Young, and J. P. Maciejewski Interferon-{gamma}-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles Blood, January 1, 2006; 107(1): 167 - 175. [Abstract] [Full Text] [PDF] A. M. Risitano New Challenges to Developing Animal Models for Human Immune-Mediated Marrow Failure Clin. Med. Res., May 1, 2005; 3(2): 63 - 64. [Full Text] [PDF] L. Wenxin, F. Jinxiang, W. Yong, L. Wenxiang, S. Wenbiao, and Z. Xueguang Expression of membrane-bound IL-15 by bone marrow fibroblast-like stromal cells in aplastic anemia Int. Immunol., April 1, 2005; 17(4): 429 - 437. [Abstract] [Full Text] [PDF] G. C. Bagby, J. M. Lipton, E. M. Sloand, and C. A. Schiffer Marrow Failure Hematology, January 1, 2004; 2004(1): 318 - 336. [Abstract] [Full Text] [PDF] W. Zeng, G. Chen, S. Kajigaya, O. Nunez, A. Charrow, E. M. Billings, and N. S. Young Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers Blood, January 1, 2004; 103(1): 325 - 332. [Abstract] [Full Text] [PDF] N. Hirano, M. O. Butler, M. S. von Bergwelt-Baildon, B. Maecker, J. L. Schultze, K. C. O'Connor, P. H. Schur, S. Kojima, E. C. Guinan, and L. M. Nadler Autoantibodies frequently detected in patients with aplastic anemia Blood, December 15, 2003; 102(13): 4567 - 4575. [Abstract] [Full Text] [PDF] J. P. Maciejewski, E. M. Sloand, O. Nunez, C. Boss, and N. S. Young Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia Blood, November 15, 2003; 102(10): 3584 - 3586. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020